Relevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the virtual J.P. Morgan Annual Health Care Conference on

Relevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the virtual J.P. Morgan Annual Health Care Conference on

Bruce C. Cozadd - Jazz Pharmaceuticals plc - Co-Founder,

distinct pleasure today to share an update on our significant accomplishments of 2020 and my excitement about this year. In 2020, thanks to the passion, innovation, integrity, collaboration and pursuit of excellence demonstrated by our 1,800

dedicated and talented employees around the world. We helped more patients, achieved record product revenues, advanced our pipeline and positioned the company for success.

With reference to Slide 2: On Slide 2,

I point out that I will be making forward-looking statements. Of course, actual results may differ materially. And the forward-looking statements are subject to risks and uncertainties that are described in our SEC filings.

With reference to Slide 7: Slide

7 reviews our topline growth over the past five years and I think nicely demonstrates our double-digit compound annual growth rates in both neuroscience and oncology. I m pleased to announce today that we do expect net sales in each franchise

to fall within our previous guidance of $1.76 billion to $1.8 billion for neuroscience and $525 million to $565 million in oncology.

With reference to Slide 8: And if we look at total revenues on Slide 8, we d like to confirm today that we expect total revenues will

fall within our previous guidance of $2.32 billion to $2.38 billion for 2020. You ll also see that we expect continued topline growth in both 2021 and 2022. Importantly, the composition of those revenues is changing significantly.

We ve stated that we expect new product sales of Sunosi , Zepzelca ,

Xywav , JZP-458, and JZP-258 to account for nearly 50 percent of our revenues by 2022. That s a

dramatic change from our revenue mix this past year.

With reference to Slide 13: Let s spend a few minutes now on each of our two TAs, starting with neuroscience. On Slide 13, we have a

snapshot of our neuroscience franchise, which we believe is poised for sustainable growth. Of course, we ve long had a strong presence in narcolepsy, but with expansion into obstructive sleep apnea with Sunosi and an upcoming launch of JZP-258

in idiopathic hypersomnia, we see additional growth in treatments for sleep disorders.

With reference to Slide 14: Let s move to Slide 14 and focus in on Xywav, where we executed on a successful launch in November. Xywav is

the only FDA-approved lower-sodium oxybate approved for the treatment of cataplexy and EDS in narcolepsy. We re out now, educating physicians and patients on the lifelong burden of narcolepsy and

high-sodium intake. Our goal for Xywav is that the majority of all oxybate patients are benefitting from Xywav by 2023.

So how s the launch going?

Very well. As we had expected, the large majority of Xywav prescriptions are for patients who ve previously taken Xyrem. We re really pleased that the majority of oxybate-na ve patients getting a new oxybate prescription are being

prescribed Xywav, and we remain on track to obtaining broad payer coverage. As you know, we were covered on Express Scripts preferred formulary at the time of launch.

With reference to Slide 20: Let s now

turn to our oncology franchise. On Slide 20, we provide a snapshot. We ve seen continued double-digit growth in this portfolio and expect future growth and diversification fueled by the recent Zepzelca launch and our planned JZP-458 launch this year. Defitelio and Vyxeos remain important therapies for patients with

significant unmet medical needs. And we have many pipeline programs exploring expanded indications for our existing agents as well as a set of innovative new targets.

With reference to Slide 21: On Slide 21, we spotlight Zepzelca, which was launched in July for the treatment of metastatic, small-cell lung cancer with

disease progression on or after platinum-based chemotherapy. It was nice to see Zepzelca immediately included in NCCN guidelines, and we received positive feedback from physicians following their use of the agent.

We had a great first quarter of launch, with $37 million in third quarter sales, with additional growth

in the fourth quarter. We believe Zepzelca has significant potential in second-line, small-cell lung cancer, where there are currently 17,000 patients a year receiving treatment, but also an additional 8,000 patients per year who ve chosen not

to receive second-line treatment based on the efficacy and tolerability of previously available treatments. And beyond that, we re excited to partner with PharmaMar to jointly develop lurbinectedin in other tumor types, and also to explore it

in first-line, small-cell lung cancer in combination with immuno-oncology and other agents.

Questions and Answers

Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Analyst

... Maybe just to build off of one of the comments that you made, Bruce, about the Xywav launch. I think you said it s going very well. Can you elaborate

that a little bit more? And maybe outline a framework to help us think about the near-term dynamics with the oxybate franchise?

Daniel N. Swisher - Jazz Pharmaceuticals plc - President & COO

... Thanks, Jess. So we just launched the product in November, but already with our well-established relationships with the sleep docs we ve had very

good engagement, both virtually and in person where possible. The focus of the business initially is patients already on Xyrem, giving them the opportunity to switch over and get on to Xywav and really get the benefit of for a lifelong therapy where

there s an increased risk of cardiovascular disease. Yes, similar strong control and efficacy control, but without those risks. I m also pleased, though, that in a short period of time, we re seeing a majority of new patients that are

coming on to oxybate therapy are coming on to Xywav over Xyrem.

So in terms of the dynamics, our focus was really educating physicians. We re just

starting to reach out now to patients that we ve established that education with physicians. It s surprising to us how few physicians actually knew how much sodium was in a Xyrem dose. And so with sodium being reducing sodium has

been a modifiable risk factor this is a real benefit on moving over to Xywav.

So we priced at parity at the launch with Xyrem. We ve got a suite of

services as we re building up contracts with the PBMs, we re very pleased that we had ESI on a preferred national formulary at the time of launch. And so that s really sort of the focus at this point is the education, the ability to

switch over and the feedback we re hearing from physicians and patients who have been using Xywav is very strong.

Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst

... [Y]ou touched on kind of the suite of services as coverage kind of comes online. And one of the questions that we re getting is kind of how to

interpret near-term oxybate revenue numbers, while you ve got this switch dynamic happening that may be either a drag on gross-to-nets or involve free bottles. So

can you kind of maybe lay out kind of what the key metrics you think are best for investors to focus on? And whether or not and maybe address just this question of whether or not folks should be concerned about maybe a kind of optically lower

revenue number in the short-term as this switch proceeds?

Bruce C. Cozadd - Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO

Yes. Before I hand it over to Dan, I ll just say, our goal

is very clear, which is to make Xywav the oxybate product over the next couple of years. And while we re certainly watching early dynamics, and I ll let Dan address your question a little more directly. At Jazz we want to make sure people

understand if they re worried about gross-to-nets in the near-term because the launch is going really well. We want to make sure patients and physicians understand

this dynamic about long-term chronic use of a high sodium product and how they make the right choices again for patients and on the physician side. Dan?

Daniel N. Swisher - Jazz Pharmaceuticals plc - President & COO

Yes. I mean, just to sort of build on what Bruce said is we ll be updating, of course, with our earnings call and providing further guidance at that

point for the oxybate franchise. We re not expecting meaningful revenue in the fourth quarter necessarily as we re ramping up patient experience and physician access. But as Bruce said, I mean, the primary driver for us is not about price.

It s really to ensure that there s a seamless transition for the patients who could benefit and we believe all patients who are currently on oxybate therapy would benefit from Xywav. And so the ability to go gram per gram and have that

transition and educate physicians and patients is the primary driver.

Jessica Macomber Fye - JPMorgan Chase & Co, Research Division

... We ve got a bunch of questions coming through on the portal. I m just going to couple some that are similar to one another.

One is, can you give any kind of number on conversion and the other one sort of read similar is what percentage of oxybate franchise patients are on Xywav?

Bruce C. Cozadd - Jazz Pharmaceuticals plc - Co-Founder, Chairman &

Yes. We ll be giving more detail, Jess, when we get to our fourth quarter call towards the end of next month. And all we re saying at

this point is we are seeing good adoption of Xywav, that most of the patients we re seeing on Xywav today do have oxybate experience in the past. But for oxybate naive patients, meaning this is their first time on either product, a majority of

them are already going to Xywav.

Fye - JPMorgan Chase & Co, Research Division - Analyst

... And then another on Zepzelca here. You ve

talked about maybe a bolus of later line patients being treated in addition to second line patients. With some eventual kind of washing out of those later line patients as the product becomes more established in second line, where are we in that

Daniel N. Swisher - Jazz Pharmaceuticals plc - President & COO

Okay. Well, we re really pleased with the way the launch has rolled out. And as we said in the presentation, we expect continued growth in sales in the

fourth quarter and our objective is to have Zepzelca be the standard of care preferred treatment option in second line patients.

Not uncommon to other,

other oncology launches at the time of launch, there s many patients that are in later lines of therapy that haven t had prior exposure to the treatment Zepzelca. And so we found through some chart reviews that we do have a certain number

of third line and later patients where 95% of their second-line treatment options were actually made before Zepzelca was available.

We do expect that now

we re getting good strong usage across all patient types, both platinum sensitive, platinum resistant, second line as well as later lines of therapy for patients who had not had prior exposure. But increasingly, we look to get patients sooner

that are probably in second line. And as you can imagine, their prognosis is better and the duration of therapy should be higher. So we re very pleased with the way the launch is going and the feedback we re getting from physicians has

been strong to date.

Relevant slides from Jazz Pharmaceuticals plc s presentation at the virtual J.P. Morgan Annual

Health Care Conference on January 11, 2021:

Jazz Pharmaceuticals

INNOVATING TO TRANSFORM THE

BRUCE COZADD, CHAIRMAN AND CEO

39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

JZP-258 Trial Participant

Life-Changing Medicines. Redefining Possibilities.

Forward -Looking Statements

Safe Harbor Statement Under The

Private Securities Litigation Reform Act of 1995

This slide deck and the accompanying oral presentation contain forward-looking statements, including, but not

limited to, statements related to Jazz Pharmaceuticals future operating results and financial condition, including 2020 financial guidance; expectations regarding the company s future revenues, cash flow, growth and revenue

diversification; the company s growth strategy, including pipeline expansion plans and corporate development efforts; ongoing, planned and potential product launches and expected or potential product sales; ongoing, planned and potential

clinical trials and other product development and regulatory activities; 2021 and future goals and objectives; the timing of the foregoing events and activities; and other statements that are not historical facts. These forward-looking statements

are based on the company s current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially fromthose anticipated in

such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the ultimate duration and severity of the COVID-19

pandemic and resulting global economic, financial and healthcare system disruptions and the current and potential future negative impacts to the company s business operations and financial results; maintaining or increasing sales of and revenue